Ixiaro (R): a new vaccine against Japanese encephalitis

作者：Jelinek Tomas^*

来源：Expert Review of Vaccines, 2009, 8(11): 1501-1511.

DOI：10.1586/ERV.09.112

• IC51
• Ixiaro (R)
• Japanese encephalitis
• vaccine

The mosquito-borne Japanese encephalitis virus (JEV) is a major threat to human health in Asia. An estimated 50,000 cases occur in the region, accounting for at least 10,000 deaths and 15,000 cases of neuropsychiatric sequelae. A new purified, inactivated JEV vaccine (IC51, Ixiaro (R)) has been developed. Since early 2009, the vaccine has been licensed in Australia, the USA and Europe. A series of successful Phase III studies has been published. Results indicate a very good safety and efficacy profile. The vaccine promises to become a modern approach to active immunization against Japanese encephalitis. With the availability of a new product, wider use of Japanese encephalitis vaccine will be prudent in the future, and guidelines and recommendations should be revised.

• 出版日期2009-11